BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29604905)

  • 1. Oncogenic RAS: From Its Activation to Its Direct Targeting.
    Zaravinos A
    Crit Rev Oncog; 2017; 22(3-4):283-301. PubMed ID: 29604905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RAS-Effector Interaction as a Drug Target.
    Keeton AB; Salter EA; Piazza GA
    Cancer Res; 2017 Jan; 77(2):221-226. PubMed ID: 28062402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugging RAS: Know the enemy.
    Papke B; Der CJ
    Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS-targeted therapies: is the undruggable drugged?
    Moore AR; Rosenberg SC; McCormick F; Malek S
    Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology, pathology, and therapeutic targeting of RAS.
    Rhett JM; Khan I; O'Bryan JP
    Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibition of RAS: Quest for the Holy Grail?
    Spencer-Smith R; O'Bryan JP
    Semin Cancer Biol; 2019 Feb; 54():138-148. PubMed ID: 29248537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
    Lv J; Wang J; Chang S; Liu M; Pang X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RASpecting the oncogene: New pathways to therapeutic advances.
    Stout MC; Campbell PM
    Biochem Pharmacol; 2018 Dec; 158():217-228. PubMed ID: 30352234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in cancer drug discovery targeting RAS.
    Wilson CY; Tolias P
    Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ras proteins as therapeutic targets.
    Chakraborty A; Linnane E; Ross S
    Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.
    Dhawan NS; Scopton AP; Dar AC
    Nature; 2016 Sep; 537(7618):112-116. PubMed ID: 27556948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics.
    Esposito D; Stephen AG; Turbyville TJ; Holderfield M
    Semin Cancer Biol; 2019 Feb; 54():174-182. PubMed ID: 29432816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting oncogenic Ras signaling in hematologic malignancies.
    Ward AF; Braun BS; Shannon KM
    Blood; 2012 Oct; 120(17):3397-406. PubMed ID: 22898602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.
    Baines AT; Lim KH; Shields JM; Lambert JM; Counter CM; Der CJ; Cox AD
    Methods Enzymol; 2006; 407():556-74. PubMed ID: 16757353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
    Delire B; Stärkel P
    Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting RAS-ERK signalling in cancer: promises and challenges.
    Samatar AA; Poulikakos PI
    Nat Rev Drug Discov; 2014 Dec; 13(12):928-42. PubMed ID: 25435214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.